PCML
SNDX icon

Pavaki Capital Management LLC’s Syndax Pharmaceuticals SNDX Stock Holding History

Pavaki Capital Management LLC’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31M Hold
60,000
– – 0.46% 43
2026
Q1 		$1.4M Hold
60,000
– – 0.6% 38
2025
Q4 		$1.26M Buy
+60,000
New +$1.05M 0.49% 40

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
VIG
Vienna Insurance Group Warsaw, Poland $381M AUM 105.39% 1-Year Est. Return

Pavaki Capital Management LLC's SNDX Position: Q2 2026 in Review

Pavaki Capital Management LLC held its Syndax Pharmaceuticals (SNDX) position steady in Q2 2026 at 60,000 shares worth $1.31M. The position accounts for 0.46% of the portfolio, ranked #43.

Pavaki Capital Management LLC first reported a position in SNDX in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.4M in Q1 2026. 67 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Pavaki Capital Management LLC held 60,000 shares of Syndax Pharmaceuticals worth $1.31M as of Q2 2026.
  • Pavaki Capital Management LLC left its Syndax Pharmaceuticals share count unchanged in Q2 2026.
  • Syndax Pharmaceuticals made up 0.46% of Pavaki Capital Management LLC's portfolio in Q2 2026, its #43 holding.
  • Pavaki Capital Management LLC first reported a position in Syndax Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Pavaki Capital Management LLC's Syndax Pharmaceuticals position peaked at $1.4M in Q1 2026.
  • 67 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Pavaki Capital Management LLC's 13F filing for Q2 2026, filed 7 Aug 2026.